CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Balance Sheet
NASDAQ:CNTA - Nasdaq - US1523091007 - ADR - Currency: USD
| MRQ (2024-6-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 127.37M | 128.03M | 393.60M | 595.10M | 7.20M | |||
| Marketable Securities | 167.46M | 128.52M | N/A | N/A | N/A | |||
| Receivables | 46.99M | 39.15M | 26.70M | 16.80M | 2.90M | |||
| Other Current Assets | 13.68M | 19.39M | 17.40M | 16.90M | 1.00M | |||
| Total Current Assets | 355.50M | 315.09M | 437.70M | 628.80M | 11.20M | |||
| Non-Current Assets | ||||||||
| PPE Net | 12.37M | 12.95M | 1.20M | 200.00K | N/A | |||
| Other Non-Current Assets | 30.97M | 32.20M | 5.40M | 700.00K | N/A | |||
| Total Non-Current Assets | 43.34M | 45.15M | 6.60M | 800.00K | 500.00K | |||
| TOTAL ASSETS | 398.85M | 360.25M | 444.30M | 629.60M | 11.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | 0.00 | 5.30M | |||
| Accrued Expenses | 21.43M | 27.46M | 22.90M | 15.80M | 1.00M | |||
| Accounts Payable | 5.32M | 11.81M | 13.80M | 8.10M | 1.00M | |||
| Other Current Liabilities | N/A | 112.00K | 1.60M | 800.00K | 900.00K | |||
| Total Current Liabilities | 26.75M | 39.38M | 38.30M | 24.60M | 8.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 76.50M | 75.70M | 69.80M | 75.70M | 0.00 | |||
| Other Non-Current Liabilities | 8.63M | 8.92M | 0.00 | 37.70M | 0.00 | |||
| Total Non-Current Liabilities | 85.13M | 84.62M | 69.80M | 113.50M | 0.00 | |||
| TOTAL LIABILITIES | 111.88M | 124.00M | 108.10M | 138.10M | 8.60M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -834.81M | -752.95M | -601.90M | -385.70M | -22.50M | |||
| Additional Paid In Capital | 1.12B | 987.42M | 939.30M | 876.30M | N/A | |||
| Common Shares | 309.00K | 273.00K | 300.00K | 300.00K | 25.50M | |||
| Other Shareholders' Equity | 1.59M | 1.49M | -1.50M | 700.00K | 100.00K | |||
| Shares Outstanding | 136.29M | 118.94M | 114.16M | 108.38M | 105.25M | |||
| Tangible Book Value per Share | 2.54 | 2.39 | 3.55 | 5.46 | -0.26 | |||
| Total Shareholders' Equity | 286.96M | 236.24M | 336.20M | 491.60M | 3.10M | |||
| TOTAL LIABILITIES AND EQUITY | 398.85M | 360.25M | 444.30M | 629.60M | 11.70M | |||
| Statistics | ||||||||
| Debt/Equity | 0.27 | 0.32 | 0.21 | 0.15 | N/A | |||
| Current Ratio | 13.29 | 8.00 | 11.43 | 25.56 | 1.30 | |||
| Return On Assets (ROA) | -39.45% | -41.94% | -48.66% | -60.53% | -91.11% | |||
| Return On Equity (ROE) | -54.83% | -63.95% | -64.31% | -77.52% | -343.87% | |||
All data in USD , ROIC based on taxRate of 0.21